Sunday, May 24, 2026
wellness India Expo
Home Tags Biosimilars

Tag: Biosimilars

BioVoice eMagazine May 2025 | Issue 5 | Volume 6

The Cover Story analyses the potential impact of significant uncertainty due to the proposed reciprocal tariffs with insights from Vishal Dhikale, Associate Vice President, Avalon Consulting. Read interview of Puneeth Kumar KT, Business Director for Planetary Health Biosolutions, Novonesis South Asia and Expert Insights by Mahesh Ramanujam, President & CEO, Global Network for Zero; and Dr Vidhi Bhanushali, CEO and Co-founder, scanO.

BioVoice eMagazine April 2025 | Issue 4 | Volume 6

The Cover Story analyzes the blockbuster opportunity for India's biopharma industry. Read interviews of Dr Cyrus Karkaria, President-Biotechnology, Lupin Limited; Sachin Joshi, MD & Founder, PharmNXT Biotech; Mandeep Singh Kumar, MD and Vice President, Medtronic India; and Harshvardhan Bhagchandka, President, IPL Biologicals

FDA approves Accord BioPharma’s biosimilar ‘IMULDOSA’ to treat chronic inflammatory conditions

Accord BioPharma (A division of Intas Pharmaceuticals) anticipates a commercial launch of IMULDOSA in the first half of 2025

Biocon Biologics report reveals strategies to boost biosimilar adoption in LMICs

GaBI Journal publishes peer-reviewed study highlighting six policy recommendations for expanding access to affordable healthcare

CPHI Pharma Awards 2024 recognize leaders and innovations in the pharma...

Fourteen categories celebrate groundbreaking achievements and introduce new honors for emerging leaders

IQVIA conducts over 45 vaccine studies in India during last 5...

The company’s success in vaccine trials is driven by its extensive site network, comprising over 130 locations across India

Biocon Biologics secures market entry for its Bmab 1200 Biosimilar in...

Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in Europe, the UK, Canada, and Japan

Eli Lilly’s Tirzepatide approved by NMPA in China, boosting market position

Tirzepatide’s debut as the first dual GIP and GLP-1 receptor agonist for obesity in China strengthens Eli Lilly’s presence

Biocon reports 30% revenue increase and ₹660 crore net profit in...

Biocon's Q1FY25 performance sees 117% EBITDA growth and ₹660 crore net profit, powered by strategic partnerships and biosimilar success

Zydus Lifesciences secures COFEPRIS approval to market MamitraTM in Mexico for...

With the approval of MamitraTM, Zydus aims to provide affordable cancer treatments for HER2-positive breast and gastric cancer patients